15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry dataR Baldassano, Harland S. Winter, Gigi Veereman et al.|Journal of Crohn s and Colitis|2013Cited by 3
P0699 EPIDEMIOLOGICAL FEATURES OF EXTRAINTESTINAL MANIFESTATIONS IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASEMelvin B. Heyman, Terry J. Smith, George D. Ferry et al.|Journal of Pediatric Gastroenterology and Nutrition|2004Cited by 1
P0613 PREMEDICATION AND INFUSION REACTIONS WITH INFLIXIMAB: RESULTS FROM A PEDIATRIC INFLAMMATORY BOWEL DISEASE CONSORTIUMJonathan E. Markowitz, Robert N. Baldassano, George D. Ferry et al.|Journal of Pediatric Gastroenterology and Nutrition|2004Cited by 1
The development of fistulizing and fibrosing complications of Crohnʼs disease in a pediatric cohortNeera Gupta, Barbara S. Kirschner, Melvin B. Heyman et al.|Inflammatory Bowel Diseases|2008Cited by 0
Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryM Dubinsky, Meena Thayu, Jeffrey Hyams et al.|Journal of Crohns & Colitis|2016Cited by 0